• By ICR Secretariat
  • Posted Thursday, August 11, 2022

How a small UK biotech ended up in Gilead’s hands

https://www.biopharmadive.com/news/gilead-mirobio-deal-autoimmune/628941/

Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal announced Thursday.